Table 1.
Patient characteristics
| Characteristic | Patients |
|---|---|
| Age (years), median (IQR), n = 186 | 68 (61–72) |
| iPSA (ng/ml), median (IQR), n = 184a | 9.7 (6.5–15.1) |
| Administered 68Ga-PSMA-11 activity (MBq), median (IQR), n = 185b | 139 (112–156) |
| Time PET to RP (day), median (IQR), n = 186 | 26 (13–46) |
| Gleason score in surgical specimen, no. (%), n = 186 | |
| 6 | 11 (5.9%) |
| 7a | 63 (33.9%) |
| 7b | 59 (31.7%) |
| 8 | 28 (15.1%) |
| 9 | 25 (13.4%) |
| Pathological stage, no. (%), n = 186 | |
| pT status | |
| 2a | 11 (5.9%) |
| 2b | 10 (5.4%) |
| 2c | 71 (38.2%) |
| 3a | 49 (26.3%) |
| 3b | 44 (23.7%) |
| 4 | 1 (0.5%) |
| pN status | |
| 0 | 154 (82.8%) |
| 1 | 32 (17.2%) |
| Surgical margin, no. (%), n = 180c | |
| Negative | 152 (84.4%) |
| Positive | 28 (15.6%) |
iPSA initial PSA, IQR interquartile range, PET positron emission tomography, PSA prostate-specific antigen, RP radical prostatectomy
aiPSA of two patients were unavailable
bThe injected dose of 68Ga-PSMA-11 from one patient was unavailable
cThe status of surgical margin from six patients were unavailable